Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Eli Lilly and Company
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 5 ans
A Single-Arm, Phase 2 Trial of Pemetrexed, Cisplatin, and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab as Maintenance, in First-Line Treatment of Nonsquamous Advanced NSCLC
The primary objective of this Phase 2 study is to assess the efficacy of pemetrexed-cisplatin combined with bevacizumab as induction therapy and pemetrexed-bevacizumab as maintenance therapy in the fi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 5 ans
A Phase 3, Open-Label, Parallel-Group Study to Compare Two Dosing Algorithms for Preprandial Human Insulin Inhalation Powder (HIIP) in Insulin-Naïve Patients with Type 2 Diabetes Mellitus
The primary objective of this study, in suboptimally-controlled insulin-naïve individuals with type 2 diabetes, is to demonstrate that a simple approach for adding HIIP to oral antihyperglycemic medic...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 5 ans
Randomized Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma who Have Had Disease Progression on Sorafenib or Are Not Eligible to Receive Sorafenib
The primary objective of this study is to characterize and compare both the time-toprogression (TTP) distributions and the effect on transforming growth factor beta (TGF--associated serum biomarke...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Eli Lilly and Company
Update Il y a 5 ans
Etude monarchE : étude de phase 3, randomisée, visant à évaluer l’abemaciclib associé à une hormonothérapie adjuvante standard comparé à une hormonothérapie adjuvante standard seule chez des patients ayant un cancer du sein de stade précoce mais de risque élevé, avec extension du cancer au niveau des ganglions, positif au récepteur hormonal (RH+) mais négatif au récepteur HER2 (HER2-). [essai clos aux inclusions]
Le cancer du sein est le cancer le plus fréquent chez la femme. 30 % des cancer du sein peuvent devenir métastatique, c’est-à-dire que les cellules cancéreuses peuvent se propager à d’autres parties d...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
,
Hormonothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 5 ans
An Open Label, Multicenter Phase 2 Study of Single-Agent Enzastaurin HCl in Previously Treated Waldenstrom’s Macroglobulinemia or Multiple Myeloma
To determine whether further study of single-agent enzastaurin is warranted in patients with previously treated WM or MM, based on RR.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited, UK
Update Il y a 5 ans
A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed plus Best Supportive Care versus Best Supportive Care Immediately Following Induction Treatment with Pemetrexed + Cisplatin for Advanced Non-Squamous Non Small Cell Lung Cancer
The primary objective of this study is to compare maintenance therapy with pemetrexed plus best supportive care (BSC) versus placebo plus BSC, in terms of objective progression-free survival (PFS) tim...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 5 ans
A Physical Dependence Study in Schizophrenia
The primary objective of this study is to assess whether LY2140023, when administered in an acute-treatment trial with flexible doses (40 or 80 mg) BID is associated with physical dependence, as measu...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 5 ans
A study in people with type 1 diabetes to determine how well a meal-time insulin, LY900014, controls diabetes compared to Humalog (insulin lispro) when both are used along with a long-acting insulin
To test the hypothesis that LY900014 is noninferior to insulin lispro on glycemic control (non-inferiority margin [NIM]=0.4% for hemoglobin A1c [HbA1c]) in patients with T1D, when administered as pran...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 5 ans
Evaluation of the blood concentration of Tabalumab after the administration of Tabalumab using prefilled syringe or auto-injector in patients with Rheumathoid Arthritis that have not responded correctly to treatment with Methotrexate
The primary objective of the study is to evaluate the effect of drug delivery method (prefilled syringe or auto-injector) on the PK of tabalumab after the administration of the loading dose in patient...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 5 ans
A study, in which patients with late stage lung cancer and changes in a gene called EGFR, will be first treated for 8 weeks with the drug erlotinib and if they have clinical benfit will receive either a combination of an experimental drug called LY2875358 plus erlotinib or erlotinib alone
The primary objective of this study is to compare PFS of LY2875358 plus erlotinib therapy with erlotinib monotherapy as first-line treatment in metastatic NSCLC patients with activating EGFRmt who hav...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
12
13
14
15
16
17
18
19
20
21
Next